Testing several drugs for tumors caused by NF2-related schwannomatosis
Original title: Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle-stage study, so these drugs are still being tested.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests several drugs in people whose NF2 tumors are growing.
Who this trial is for. This trial is for people with NF2-related schwannomatosis whose schwannomas, meningiomas, or ependymomas are growing. It tests brigatinib, neratinib, and retifanlimab with bevacizumab in separate parts of the study.
Where it stands. The trial has not reported results. It is testing whether these drugs help with these tumors. That answer is not in yet.
What this means, and what it doesn't
What it could mean: Someone with NF2-related schwannomatosis and growing tumors may fit this study. It is fair to ask your care team about it.
What it doesn't mean: A trial is a test, not a proven treatment. Being in one does not mean it will help you. It is not a promise of a cure.
Source: ClinicalTrials.gov, September 2, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.